Assessment of Reactive Metabolites in Drug-Induced Liver Injury
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Kye Sook | - |
dc.contributor.author | Oh, Soo Jin | - |
dc.contributor.author | Kim, Hwan Mook | - |
dc.contributor.author | Lee, Ki Ho | - |
dc.contributor.author | Kim, Sang Kyum | - |
dc.date.accessioned | 2021-09-07T06:33:17Z | - |
dc.date.available | 2021-09-07T06:33:17Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2011-11 | - |
dc.identifier.issn | 0253-6269 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/111217 | - |
dc.description.abstract | The aim of the current review is to summarize present methods used for the determination of reactive metabolites, which can predict drug-induced liver injury (DILI) in drug discovery and development. DILI is one of the most frequent reasons for the withdrawal of an approved drug from the market, and it accounts for up to 50% of acute liver failure cases. This review is structured into three sections. The first section is a general overview of the relationship between drug metabolism and liver injury. The second section introduces in vitro methods for the assessment of reactive metabolites for drug discovery and development. In the third section, limitations and future directions for the development of methods for predicting DILI are described. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | PHARMACEUTICAL SOC KOREA | - |
dc.subject | HUMAN SERUM-ALBUMIN | - |
dc.subject | DIFLUNISAL ACYL GLUCURONIDE | - |
dc.subject | COVALENT BINDING | - |
dc.subject | IN-VITRO | - |
dc.subject | MECHANISMS | - |
dc.subject | TOXICITY | - |
dc.subject | IDENTIFICATION | - |
dc.subject | DISPOSITION | - |
dc.subject | TOXICOLOGY | - |
dc.subject | CYTOCHROME-P450 | - |
dc.title | Assessment of Reactive Metabolites in Drug-Induced Liver Injury | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Ki Ho | - |
dc.identifier.doi | 10.1007/s12272-011-1108-x | - |
dc.identifier.scopusid | 2-s2.0-83655180983 | - |
dc.identifier.wosid | 000297650300010 | - |
dc.identifier.bibliographicCitation | ARCHIVES OF PHARMACAL RESEARCH, v.34, no.11, pp.1879 - 1886 | - |
dc.relation.isPartOf | ARCHIVES OF PHARMACAL RESEARCH | - |
dc.citation.title | ARCHIVES OF PHARMACAL RESEARCH | - |
dc.citation.volume | 34 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 1879 | - |
dc.citation.endPage | 1886 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART001603645 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | HUMAN SERUM-ALBUMIN | - |
dc.subject.keywordPlus | DIFLUNISAL ACYL GLUCURONIDE | - |
dc.subject.keywordPlus | COVALENT BINDING | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | MECHANISMS | - |
dc.subject.keywordPlus | TOXICITY | - |
dc.subject.keywordPlus | IDENTIFICATION | - |
dc.subject.keywordPlus | DISPOSITION | - |
dc.subject.keywordPlus | TOXICOLOGY | - |
dc.subject.keywordPlus | CYTOCHROME-P450 | - |
dc.subject.keywordAuthor | Acyl glucuronide | - |
dc.subject.keywordAuthor | Drug-induced liver injury | - |
dc.subject.keywordAuthor | Drug metabolism | - |
dc.subject.keywordAuthor | Mechanism-based inhibition | - |
dc.subject.keywordAuthor | Reactive metabolites | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.